Shares of Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) traded down 5.7% during trading on Friday . The stock traded as low as $14.51 and last traded at $14.62. 177,479 shares were traded during mid-day trading, a decline of 63% from the average session volume of 481,693 shares. The stock had previously closed at $15.51.
Wall Street Analysts Forecast Growth
A number of analysts have recently weighed in on the company. Leerink Partners began coverage on Beta Bionics in a research report on Monday, February 24th. They set an "outperform" rating and a $28.00 price objective on the stock. Lake Street Capital began coverage on Beta Bionics in a report on Monday, February 24th. They set a "buy" rating and a $30.00 price target on the stock. Bank of America began coverage on Beta Bionics in a research report on Monday, February 24th. They issued a "buy" rating on the stock. Stifel Nicolaus initiated coverage on Beta Bionics in a research report on Monday, February 24th. They set a "buy" rating and a $25.00 price objective for the company. Finally, Robert W. Baird assumed coverage on shares of Beta Bionics in a report on Thursday, February 20th. They issued a "neutral" rating and a $20.00 target price on the stock. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Beta Bionics has an average rating of "Moderate Buy" and a consensus target price of $24.83.
View Our Latest Stock Report on Beta Bionics
Beta Bionics Price Performance
The business has a 50 day moving average of $12.41.
Beta Bionics (NASDAQ:BBNX - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.01).
Institutional Investors Weigh In On Beta Bionics
Institutional investors and hedge funds have recently bought and sold shares of the stock. Eventide Asset Management LLC acquired a new stake in shares of Beta Bionics during the first quarter worth about $60,307,000. Wellington Management Group LLP purchased a new position in Beta Bionics during the 1st quarter worth approximately $47,346,000. Sands Capital Ventures LLC purchased a new position in Beta Bionics during the 1st quarter worth approximately $37,990,000. Omega Fund Management LLC purchased a new stake in Beta Bionics in the first quarter valued at approximately $24,337,000. Finally, Driehaus Capital Management LLC purchased a new stake in Beta Bionics in the first quarter valued at approximately $10,799,000.
About Beta Bionics
(
Get Free Report)
Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Beta Bionics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beta Bionics wasn't on the list.
While Beta Bionics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
